Get the app
US › Healthcare

TuHURA Biosciences Inc (HURA)

US · Healthcare · Biotechnology

$2.09+2.96%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-9.2M
EPS
$-0.14
EPS estimate
$-0.15

EPS came in at -0.14 against a street estimate of -0.15 — a beat of 6.7%.

Key statistics

Market cap
$129.4M
Forward P/E
0.0
P/B
7.19
Book value
$0.29
EPS (TTM)
$-0.53
52-week high
$3.43
52-week low
$0.41
50-day MA
$2.18
200-day MA
$1.82

Analyst view

Analysts rate TuHURA Biosciences Inc a buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $8.04.

Shareholding

Insiders
34.62%
Institutions
14.19%

Largest institutional holders

FundStake
BlackRock Inc3.85%
Vanguard Capital Management, LLC3.26%
Geode Capital Management, LLC1.55%
AQR Capital Management LLC0.95%
State Street Corp0.81%
Millennium Management LLC0.71%
Northern Trust Corp0.47%
Vanguard Fiduciary Trust Co0.45%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for TuHURA Biosciences Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.